← 返回专利悬崖列表
CAS 123-08-0
4-hydroxybenzaldehyde4-Formylphenol4-Hydroxybenzaldehyde
登记编号：PIMAV-001、Tamsulosin Hydrochloride-022、SAFI-002、BAZE-010、PIOG-015、Bisoprolol-015、FEBU-016、HYPIL-006
应用背景（按来源药适应症）
妄想酒石酸匹莫范色林幻觉酒石酸匹莫范色林勃起功能障碍他达拉非/坦洛新前列腺增生他达拉非/坦洛新帕金森病甲磺酸沙非胺疼痛甲磺酸沙非胺药物性运动障碍甲磺酸沙非胺肝功能衰退甲磺酸沙非胺多系统萎缩甲磺酸沙非胺肾功能不全甲磺酸沙非胺下尿路症状琥珀酸索利那新/盐酸坦洛新前列腺增生琥珀酸索利那新/盐酸坦洛新膀胱过度活动症琥珀酸索利那新/盐酸坦洛新药物相关的副作用和不良反应琥珀酸索利那新/盐酸坦洛新膀胱颈梗阻琥珀酸索利那新/盐酸坦洛新雌激素缺乏综合征结合雌激素/醋酸巴多昔芬骨质疏松症结合雌激素/醋酸巴多昔芬血管舒缩症结合雌激素/醋酸巴多昔芬非浸润性导管癌结合雌激素/醋酸巴多昔芬焦虑结合雌激素/醋酸巴多昔芬绝经期症状结合雌激素/醋酸巴多昔芬二型糖尿病苯甲酸阿格列汀/盐酸吡格列酮前列腺增生度他雄胺/盐酸坦洛新高血压苯磺酸氨氯地平/富马酸比索洛尔原发性高血压苯磺酸氨氯地平/富马酸比索洛尔高尿酸血症非布司他痛风非布司他颅内出血非布司他溃疡性结肠炎非布司他慢性肾功能不全非布司他疼痛非布司他前列腺增生盐酸坦洛新泌尿系统感染盐酸坦洛新尿潴留盐酸坦洛新腹股沟疝盐酸坦洛新排尿功能障碍盐酸坦洛新下尿路症状盐酸坦洛新绝经期后骨质疏松醋酸巴多昔芬乳腺癌醋酸巴多昔芬骨质疏松症醋酸巴多昔芬绝经期症状醋酸巴多昔芬二型糖尿病盐酸吡格列酮肺性高血压盐酸吡格列酮乳腺癌盐酸吡格列酮非酒精性脂肪性肝炎盐酸吡格列酮可卡因成瘾盐酸吡格列酮酗酒盐酸吡格列酮高血压富马酸比索洛尔心绞痛富马酸比索洛尔慢性阻塞性肺疾病富马酸比索洛尔心脏和血管疾病富马酸比索洛尔急性冠脉综合征富马酸比索洛尔禁食富马酸比索洛尔肾上腺脑白质营养不良Leriglitazone弗里德赖希共济失调Leriglitazone
来源药（使用该中间体的合成路线）
| 品种 | 梯队 | 到期年 |
|---|---|---|
| 酒石酸匹莫范色林Pimavanserin Tartrate | Tier C · 观察 / 贸易 | 2029 |
| 他达拉非/坦洛新Tadalafil/Tamsulosin | Tier C · 观察 / 贸易 | - |
| 甲磺酸沙非胺Safinamide Mesylate | Tier C · 观察 / 贸易 | - |
| 琥珀酸索利那新/盐酸坦洛新Solifenacin Succinate/Tamsulosin Hydrochloride | Tier C · 观察 / 贸易 | - |
| 结合雌激素/醋酸巴多昔芬Conjugated Estrogens/Bazedoxifene Acetate | Tier C · 观察 / 贸易 | - |
| 苯甲酸阿格列汀/盐酸吡格列酮Alogliptin Benzoate/Pioglitazone Hydrochloride | Tier C · 观察 / 贸易 | - |
| 度他雄胺/盐酸坦洛新Dutasteride/Tamsulosin Hydrochloride | Tier C · 观察 / 贸易 | - |
| 苯磺酸氨氯地平/富马酸比索洛尔Amlodipine Besylate/Bisoprolol Fumarate | Tier C · 观察 / 贸易 | - |
| 非布司他Febuxostat | Tier C · 观察 / 贸易 | - |
| 盐酸坦洛新Tamsulosin Hydrochloride | Tier C · 观察 / 贸易 | - |
| 醋酸巴多昔芬Bazedoxifene Acetate | Tier C · 观察 / 贸易 | - |
| 盐酸吡格列酮Pioglitazone Hydrochloride | Tier B · 提前布局 | - |
| 富马酸比索洛尔Bisoprolol Fumarate | Tier C · 观察 / 贸易 | - |
| Leriglitazone | Tier C · 观察 / 贸易 | - |
合成路线中的位置（上下游链）
按路线登记顺序排列，左→右为合成方向；高亮为当前 CAS，其余可点击跳转对应档案。
4-hydroxybenzaldehyde→1-bromo-2-methylpropane→4-isobutoxybenzaldehyde→(E)-4-isobutoxybenzaldehyde oxime→(4-isobutoxyphenyl)methanamine→1-isobutoxy-4-(isocyanatomethyl)benzene→N-(4-fluorobenzyl)-1-methylpiperidin-4-amine→1-methylpiperidin-4-one→(4-fluorophenyl)methanamine→sodium triacetoxyhydroborate
5-(2(R)-Aminopropyl)-2-methoxybenzenesulfonamide→Benzaldehyde→4-Methoxybenzaldehyde→4-Formylphenol→(4-Fluorophenyl)methanone→2-methoxy-5-[(2R)-2-[(E)-(phenylmethylidene)amino]propyl]benzene-1-sulfonamide→2-Methoxy-5-[(2R)-2-[(E)-[(4-methoxyphenyl)methylidene]amino]propyl]benzene-1-sulfonamide→5-[(2R)-2-[(E)-[(4-Hydroxyphenyl)methylidene]amino]propyl]-2-methoxybenzene-1-sulfonamide→5-[(2R)-2-[(E)-[(4-Fluorophenyl)methylidene]amino]propyl]-2-methoxybenzene-1-sulfonamide→1-ethoxy-2-(2-iodoethoxy)benzene→(E)-[2-(2-ethoxyphenoxy)ethyl][(2R)-1-(4-methoxy-3-sulfamoylphenyl)propan-2-yl](phenylmethylidene)azanium iodide→(2R)-N-[2-(2-Ethoxyphenoxy)ethyl]-N-[(E)-(4-methoxyphenyl)methylidene]-1-(4-methoxy-3-sulfamoylphenyl)propan-2-iminium iodide→(2R)-N-[2-(2-Ethoxyphenoxy)ethyl]-N-[(E)-(4-hydroxyphenyl)methylidene]-1-(4-methoxy-3-sulfamoylphenyl)propan-2-iminium iodide→(2R)-N-[2-(2-Ethoxyphenoxy)ethyl]-N-[(E)-(4-fluorophenyl)methylidene]-1-(4-methoxy-3-sulfamoylphenyl)propan-2-iminium iodide→(-)-5-[2(R)-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide
5-(2(R)-Aminopropyl)-2-methoxybenzenesulfonamide→Benzaldehyde→4-Methoxybenzaldehyde→4-Formylphenol→(4-Fluorophenyl)methanone→2-methoxy-5-[(2R)-2-[(E)-(phenylmethylidene)amino]propyl]benzene-1-sulfonamide→2-Methoxy-5-[(2R)-2-[(E)-[(4-methoxyphenyl)methylidene]amino]propyl]benzene-1-sulfonamide→5-[(2R)-2-[(E)-[(4-Hydroxyphenyl)methylidene]amino]propyl]-2-methoxybenzene-1-sulfonamide→5-[(2R)-2-[(E)-[(4-Fluorophenyl)methylidene]amino]propyl]-2-methoxybenzene-1-sulfonamide→1-ethoxy-2-(2-iodoethoxy)benzene→(E)-[2-(2-ethoxyphenoxy)ethyl][(2R)-1-(4-methoxy-3-sulfamoylphenyl)propan-2-yl](phenylmethylidene)azanium iodide→(2R)-N-[2-(2-Ethoxyphenoxy)ethyl]-N-[(E)-(4-methoxyphenyl)methylidene]-1-(4-methoxy-3-sulfamoylphenyl)propan-2-iminium iodide→(2R)-N-[2-(2-Ethoxyphenoxy)ethyl]-N-[(E)-(4-hydroxyphenyl)methylidene]-1-(4-methoxy-3-sulfamoylphenyl)propan-2-iminium iodide→(2R)-N-[2-(2-Ethoxyphenoxy)ethyl]-N-[(E)-(4-fluorophenyl)methylidene]-1-(4-methoxy-3-sulfamoylphenyl)propan-2-iminium iodide→(-)-5-[2(R)-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide
5-(benzyloxy)-2-(4-(benzyloxy)phenyl)-3-methyl-1H-indole→1-(4-(2-(azepan-1-yl)ethoxy)benzyl)-5-(benzyloxy)-2-(4-(benzyloxy)phenyl)-3-methyl-1H-indole→4-hydroxybenzaldehyde→1-(2-chloroethyl)azepane hydrochloride→4-(2-(azepan-1-yl)ethoxy)benzaldehyde→(4-(2-(azepan-1-yl)ethoxy)phenyl)methanol→1-(2-(4-(chloromethyl)phenoxy)ethyl)azepane hydrochloride
本站可供应的对应中间体
同 CAS 多家在售供应横向对比；价格区间为供应方挂牌口径，实价以询价确认为准。
| 供应商 | 产品 | 价格区间 | 最小起订 | 货期 | 资质 | 操作 |
|---|---|---|---|---|---|---|
| Qualified Partner — East China API Works | Ethyl 2-(3-Formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Unibest Nantong cGMP Site | Ethyl 2-(4-hydroxyphenyl)-4-methylthiazole-5-carboxylate Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
本页为中间体 CAS 注册档案：同 CAS 的多条路线登记已合并；后续供应商报价与买方需求以该 CAS 为主键撮合。